Oral Oresentation 4

3:30 PM - 3:36 PM JST(6:30 AM - 6:36 AM UTC)

[O04-01] Efficacy and safety of Mirikizumab versus placebo in East Asian patients with moderately-to-severely active Crohn's disease: a post hoc sub-analysis of the global phase 3 VIVID-1 study

Minhu Chen¹, Qian Cao², Wenjia Liu³, Deliang Liu⁴, Marc Ferrante⁵, Tae Oh Kim⁶, Wentao Luo⁷, Masaru Tanaka⁸, Hilde Carlier⁹, Jiao Yu⁷, Jiawei Xu⁷, *Tadakazu Hisamatsu¹⁰ (1. The First Affiliated Hospital of Sun Yat-sen University, Guangzhou, China , 2. Sir Run Run Shaw Hospital, Hangzhou, China, 3. The Second People’s Hospital of Changzhou- the Third Affiliated Hospital of Nanjing Medical University, Changzhou, China, 4. The Second Xiangya Hospital of Central South University, Changsha, China, 5. University Hospitals Leuven, KU Leuven, Leuven, Belgium, 6. Inje University Haeundae Paik Hospital, Busan, South Korea, 7. Eli Lilly and Company, Shanghai, China , 8. Eli Lilly Japan K.K., Kobe, 9. Eli Lilly and Company, Indianapolis, IN, USA, 10. Kyorin University School of Medicine, Tokyo, Japan)

Password required to view

Enter the password to view the abstracts.
The password will be emailed to those who have completed the registration.